Allogeneic Hematopoietic Cell Transplant (Allo-HCT) for Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma: The University of Michigan Experience
Year: 2014
Type: article
Study design: Observational Study
Abstract: The treatment of advanced refractory DLBCL remains a major challenge. High dose therapy with autologous stem cell transplant (HDT/ASCT) has a limited role only in chemosensitive relapsed disease, with a curative potential of 25-50%. No therapy has proven to be effective long-term for advanced chemo-refractory DLBCL. Although allo-HCT has curative potential, historically, the outcomes remain unsatisfactory due to high treatment related mortality (TRM) after myeloablative conditioning (MAC), high relapse rate after reduced-intensity conditioning (RIC) regimens and the concern for a less potent graft-versus-lymphoma effect (GVL) A total of 97 DLBCL patients (pts) [M64:F33] undergoing allo-HCT at UM between 1996 and 2011 were retrospectively evaluated.
Institution: University of Michigan
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2099135203